Develops monoclonal antibodies for autoimmune diseases.
Dec 2025Revenue $800K/yrExpenses $49.3M/yr
No trendCash runway ≈ 2.6 years from Jun 2026
Figures by year
When will ImageneBio be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $800K and expenses $49.3M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $800K | $49.3M | −$48.5M |
| Dec 2024 | $3.50M | $40.5M | −$37.0M |
| Dec 2023 | $9.16M | $84.6M | −$75.4M |
| Dec 2022 | $15.6M | $86.5M | −$70.9M |
| Dec 2021 | $31.0M | $65.1M | −$34.1M |
| Dec 2020 | $9.19M | $53.7M | −$44.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.